ArticleJournal of neuro-oncology2020
GD2 targeting by dinutuximab beta is a promising immunotherapeutic approach against malignant glioma.
Sascha Marx et al.PubMed ↗Publisher ↗
No numbers read from the abstract.
15 papers cite it
this papercites it
ArticleJournal of neuro-oncology2020
Sascha Marx et al.PubMed ↗Publisher ↗
No numbers read from the abstract.